Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/nab-paclitaxel chemoradiation followed by conversion surgery in unresectable locally advanced pancreatic cancer
jRCTs051210167Phase 2Recruiting
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) (2 arms). Primary endpoint: Overall survival. Started Feb 2022; status: recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs051210167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210167.